A Study to Evaluate Immunogenicity and Safety of Boostrix When co-Administered With Fluarix in Subjects 19 Years of Age and Older.

Trial Profile

A Study to Evaluate Immunogenicity and Safety of Boostrix When co-Administered With Fluarix in Subjects 19 Years of Age and Older.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs DTaP vaccine; Influenza virus vaccine
  • Indications Diphtheria; Influenza virus infections; Pertussis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 03 Feb 2012 Actual end date (Feb 2007) added as reported by ClinicalTrials.gov.
    • 03 Feb 2012 Actual patient number is 1726 according to ClinicalTrials.gov.
    • 30 Dec 2011 Results for the exploratory cohort of subjects aged 65 years or older published in Vaccine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top